Bispecific antibodies
Bispecific antibodies are engineered antibody therapeutics designed to bind two distinct molecular targets or epitopes.
Bispecific antibodies are engineered antibody therapeutics designed to bind two distinct molecular targets or epitopes. By bringing two interacting components into proximity, they can redirect immune cells, block complementary biological pathways, or enhance neutralization of infectious agents. In cancer immunotherapy, antibodies targeting a tumor-associated antigen and CD3+ T cells can recruit T cells to tumor cells, while T-cell receptor (TCR)-mimic bispecific antibodies can recognize selected peptide–HLA complexes and redirect T-cell cytotoxicity. These approaches are being investigated in hematologic and solid cancers, including relapsed/refractory multiple myeloma, and in combination or sequence with chimeric antigen receptor T-cell therapy.
Other bispecific designs target two conserved viral epitopes to broaden neutralization, including preclinical constructs directed against H7 avian influenza and severe fever with thrombocytopenia syndrome virus. Bispecific antibodies are also being developed to disrupt tumor–stroma interactions, such as those involving FAP and TREM2, and to combine β-nerve growth factor and TNFR2 binding. Their development therefore spans cancer immunotherapy, antiviral treatment, and modulation of disease-associated cellular niches; characterization of anti-drug antibodies and domain-specific neutralizing antibodies is relevant to their clinical evaluation.
Where the papers sit
10 papers from the last 6 months study bispecific antibodies directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 2 observational · 1 human data · 6 preclinical · 1 unclassified
Themes 3 themes · 1 paradigm shift · 1 new direction
-
Antibody-Mediated Viral Protection
Bispecific antibody development is moving toward broad neutralization, prophylaxis, and resistance-limiting viral protection. Conserved hemagglutinin targeting protects against H7 avian influenza, while another antibody provides complete preclinical protection against SFTSV. Fc engineering and mRNA delivery are being used to multiplex antibody production and constrain viral escape. A β-NGF/TNFR2 binding assay reflects parallel efforts to characterize therapeutic antibody responses.
4 papers · 40%
-
Cancer T-Cell Immunity
TCR-directed immune targeting is being refined through peptide-HLA-mimic antibodies and CD3-bispecific approaches. DNA hypomethylating agents are used to preserve T-cell stemness and improve antitumor activity. Single-cell and spatial multi-omics instead map tumor-stroma niches involving tumor-associated macrophages and treatment resistance. The shared direction is mechanism-guided cancer immunotherapy, although the resistance biology remains broader than bispecific treatment alone.
3 papers · 30%
-
Multiple Myeloma Immunotherapy
CAR-T therapy and bispecific antibodies are being evaluated as single and sequential treatments for relapsed or refractory multiple myeloma. Treatment sequencing is increasingly linked to long-term survival in patients receiving fourth-line or later therapy. Clinical course and risk factors, including central nervous system involvement, remain important for interpreting response. The evidence supports individualized sequencing rather than a settled winner between the two modalities.
3 papers · 30%
Antigenic evolution need not make antibody protection narrow or transient when bispecifics combine conserved, non-overlapping viral targets
The SARS-CoV-2 mRNA-encoded bispecific-antibody study 42873897Oct and the H7 avian-influenza BsAb-H7 study 42617142Aug each found, in different viral systems, that escape-prone monoclonal-antibody protection could instead be made broad and more durable by engaging multiple conserved epitopes: the SARS-CoV-2 approach used multiplexed mRNA delivery of three bispecifics to neutralize historical and contemporary variants, while BsAb-H7 targeted two conserved H7 hemagglutinin epitopes and protected against divergent subtypes. This replaces the assumption that ongoing viral antigenic change necessarily defeats antibody prophylaxis with a strategy in which structural epitope selection and antibody multiplexing are used to constrain escape and preserve protection.
Bispecific antibodies can be used to dismantle a spatial tumor–stroma resistance niche rather than chiefly to neutralize pathogens or redirect cytotoxic T cells
The FAP/TREM2 bispecific antibody developed for multidrug-resistant melanoma targets the interacting fibroblast and macrophage components of a recurrent tumor–stroma interface, disrupting the CXCL14–TREM2-associated niche and restoring treatment sensitivity in patient-derived xenografts. This assigns bispecific antibodies a distinct role as spatial microenvironment remodelers that reverse established therapeutic resistance, rather than as direct antiviral neutralizers or tumor-cell-directed T-cell engagers 42748914Sep.
Papers
The 10 papers from the last 6 months that study bispecific antibodies directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Antibody-Mediated Viral Protection (4)
- Orthogonal Fc engineering enables multiplexed delivery of mRNA-encoded bispecific antibodies that constrain viral escape. Science translational medicine · 14 Oct 2026 PMID 42873897
- A highly potent bispecific antibody confers complete protection against SFTSV in preclinical models. Proceedings of the National Academy of Sciences of the United States of America · 30 Sept 2026 PMID 42814544
- A Novel Neutralizing-antibody Assay for Detection of β-NGF Binding Domain-specific Antibodies Against a β-NGF/TNFR2 Bispecific Therapeutic Antibody. The AAPS journal · 9 Sept 2026 PMID 42711599
- A bispecific antibody targeting conserved hemagglutinin epitopes confers broad protection against H7 avian influenza and accelerates viral clearance via localized respiratory delivery. Emerging microbes & infections · 19 Aug 2026 PMID 42617142
Cancer T-Cell Immunity (3)
- Single-cell and spatial multi-omics reveal a recurrent multicellular niche at the tumor-stroma interface in multidrug resistance. Cell reports. Medicine · 16 Sept 2026 PMID 42748914
- Discovery and engineering of bispecific TCR-mimic antibodies targeting peptide-HLA complex. mAbs · 12 Sept 2026 PMID 42731891
- DNA Hypomethylating Agents Preserve T-cell Stemness and Potentiate the Efficacy of CD3-Bispecific Antibodies. Cancer immunology research · 11 Jun 2026 PMID 42275524
Multiple Myeloma Immunotherapy (3)
- Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement. Blood advances · 25 Jun 2026 PMID 42348786
- Impact of Treatment Sequencing With CAR T-cell Therapies and Bispecific Antibodies on Long-term Survival in 4L+ RRMM in the United States: A Simulation Model. Clinical lymphoma, myeloma & leukemia · 24 Jun 2026 PMID 42342528
- Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma. Blood cancer discovery · 12 Jun 2026 PMID 42284467
By study type
Observational studies and case reports (2)
- Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement. Blood advances · 25 Jun 2026 PMID 42348786
- Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma. Blood cancer discovery · 12 Jun 2026 PMID 42284467
Human data, design not indexed (1)
- Impact of Treatment Sequencing With CAR T-cell Therapies and Bispecific Antibodies on Long-term Survival in 4L+ RRMM in the United States: A Simulation Model. Clinical lymphoma, myeloma & leukemia · 24 Jun 2026 PMID 42342528
Preclinical: animal, cell and lab studies (6)
- Orthogonal Fc engineering enables multiplexed delivery of mRNA-encoded bispecific antibodies that constrain viral escape. Science translational medicine · 14 Oct 2026 PMID 42873897
- A highly potent bispecific antibody confers complete protection against SFTSV in preclinical models. Proceedings of the National Academy of Sciences of the United States of America · 30 Sept 2026 PMID 42814544
- Discovery and engineering of bispecific TCR-mimic antibodies targeting peptide-HLA complex. mAbs · 12 Sept 2026 PMID 42731891
- A Novel Neutralizing-antibody Assay for Detection of β-NGF Binding Domain-specific Antibodies Against a β-NGF/TNFR2 Bispecific Therapeutic Antibody. The AAPS journal · 9 Sept 2026 PMID 42711599
- A bispecific antibody targeting conserved hemagglutinin epitopes confers broad protection against H7 avian influenza and accelerates viral clearance via localized respiratory delivery. Emerging microbes & infections · 19 Aug 2026 PMID 42617142
- DNA Hypomethylating Agents Preserve T-cell Stemness and Potentiate the Efficacy of CD3-Bispecific Antibodies. Cancer immunology research · 11 Jun 2026 PMID 42275524
Unclassified: not yet indexed with MeSH (1)
- Single-cell and spatial multi-omics reveal a recurrent multicellular niche at the tumor-stroma interface in multidrug resistance. Cell reports. Medicine · 16 Sept 2026 PMID 42748914
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-10-02. Drafted by language models from published abstracts; not medical advice.